These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 11283121

  • 21. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N.
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 23. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
    Hsu Y, Sood AK, Sorosky JI.
    Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
    [Abstract] [Full Text] [Related]

  • 24. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
    Ebata T, Yunokawa M, Bun S, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
    [Abstract] [Full Text] [Related]

  • 25. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [Abstract] [Full Text] [Related]

  • 26. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
    Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes Ed, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ.
    J Clin Oncol; 2000 Jul; 18(14):2733-9. PubMed ID: 10894873
    [Abstract] [Full Text] [Related]

  • 27. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
    Pokrzywinski R, Secord AA, Havrilesky LJ, Puls LE, Holloway RW, Lewandowski GS, Higgins RV, Nycum LR, Kohler MF, Revicki DA.
    Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C.
    Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Kietpeerakool C, Suprasert P, Srisomboon J.
    J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
    [Abstract] [Full Text] [Related]

  • 38. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME.
    Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS.
    Gynecol Oncol; 2011 May 01; 121(2):264-8. PubMed ID: 21277623
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.